The mania surrounding Valeant Pharmaceuticals International hit its peak a year ago. Strange as it may seem today after all that has happened, on Aug. 5, 2015 — two weeks after a dazzling second-quarter earnings report — the drug company’s stock closed at $262.52.
J. Michael Pearson, Valeant’s chairman and chief executive at the time, took a victory lap when he announced those earnings. “We once again exceeded our guidance and delivered our fourth consecutive quarter of greater than 15 percent organic growth,” he said.
J. Michael Pearson, Valeant’s chairman and chief executive at the time, took a victory lap when he announced those earnings. “We once again exceeded our guidance and delivered our fourth consecutive quarter of greater than 15 percent organic growth,” he said.